| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Wang,Su-Qi | Chairman | 34.24% | Center Laboratories, Inc. |
| Zheng,Wan-Lai | Director | 34.24% | Center Laboratories, Inc. |
| Bioengine Technology Development Inc. | Director | 0.62% | |
| SHUN CHENG PHARMACEUTICAL LTD. | Director | 0.00% | |
| Wang,Xue-Ling | Director | 0.28% | |
| Jin,Zhi-Yong | Independent Director | 0.00% | |
| Wu,Zhi-Xiong | Independent Director | 0.00% | |
| Ma,Hai-Yi | Independent Director | 0.00% | |
| Lin,Xin-Rong | Independent Director | 0.00% |
Change Company Name to LUMOSA THERAPEUTICS CO., LTD.
2024/06/03
Change Person in Charge to Wang,Su-Qi
2024/06/03
Change Company Name to SHUNTIAN PHARMACEUTICAL BIOTECHNOLOGY CO., LTD. (FORMER NAME: SHUNTIAN BIOTECHNOLOGY CO., LTD.)
2022/08/26
Change Capital to 3,000,000,000
2022/01/11
Change Capital to 2,000,000,000
2021/08/31
Change Capital to 3,000,000,000
2021/08/23
Change Person in Charge to Lin,Rong-Jin
2021/08/23
Change Capital to 2,000,000,000
2019/01/07
Change Person in Charge to Cai,Zhang-Hai
2016/04/07
Change Company Name to LUMOSA THERAPEUTICS CO., LTD.
2014/08/04
Change Capital to 1,000,000,000
2014/08/04
Change Person in Charge to Lin,Rong-Jin
2011/10/19
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 8,896 | 39,154 | 56,916 |
| Operating cost | 3,706 | 21,441 | 15,435 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 5,190 | 17,713 | 41,481 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 5,190 | 17,713 | 41,481 |
| Operating expenses | 111,619 | 374,833 | 417,258 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -106,429 | -357,120 | -375,777 |
| Non-operating income and expenses | 1,026 | -79,716 | 125,691 |
| Net profit (loss) before tax | -105,403 | -436,836 | -250,086 |
| Income tax expense (benefits) | 0 | 0 | 248 |
| Net profit (loss) of ongoing business for the current period | -105,403 | -436,836 | -250,334 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -105,403 | -436,836 | -250,334 |
| Other comprehensive profit (loss), net | 28 | 47 | -26 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -105,375 | -436,789 | -250,360 |
| Net profit (loss) attributable to owners of parent company | -104,186 | -424,784 | -238,041 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | -1,217 | -12,052 | -12,293 |
| Comprehensive profit (loss) attributable to owners of parent company | -104,158 | -424,737 | -238,067 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | -1,217 | -12,052 | -12,293 |
| Basic earnings per share (yuan) | 0 | -2 | -1 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -81,044 | -296,326 | -328,213 |
| Net cash inflows (outflows) from investing activities | 100,000 | -787,100 | 240,584 |
| Net cash inflow (outflow) from financing activities | -1,684 | 893,617 | -3,945 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 28 | 47 | -26 |
| Increase (decrease) in cash and cash equivalents in the current period | 17,300 | -189,762 | -91,600 |
| Beginning balance of cash and cash equivalents | 235,486 | 425,248 | 516,848 |
| Ending balance of cash and cash equivalents | 252,786 | 235,486 | 425,248 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 1,460,295 | 1,537,047 | 1,044,034 |
| Non-current asset | 594,427 | 595,914 | 612,245 |
| Total asset | 2,054,722 | 2,132,961 | 1,656,279 |
| Current liability | 221,101 | 201,176 | 219,577 |
| Non-current liability | 5,204 | 4,281 | 8,117 |
| Total liability | 226,305 | 205,457 | 227,694 |
| share capital | 1,688,168 | 1,688,968 | 1,649,738 |
| Equity - secruity token | - | - | - |
| capital reserve | 2,219,198 | 2,223,217 | 1,362,550 |
| retained earning | -2,023,108 | -1,918,922 | -1,494,138 |
| Other equity | -70,459 | -81,594 | -117,452 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 1,813,799 | 1,911,669 | 1,400,698 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | 14,618 | 15,835 | 27,887 |
| Total Equity | 1,828,417 | 1,927,504 | 1,428,585 |
| Share capital awaiting retirement (unit: share) | 80,000 | - | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 10 | 11 | 8 |
| 標案名稱 | 機關名稱 | 決標日期 | 決標金額 | 是否得標 |
|---|---|---|---|---|
| 試驗藥品生產 | 國防醫學院 | 103/10/28 | 3900000.0 | 是 |
